Ghassan Abou-Alfa, MD
GI Oncology Service
Memorial Sloan Kettering Cancer Centre
Weill Cornell Medical College
Chair, NCI Task Force for Hepatobiliary Cancers
New York, NY
Ghassan K. Abou-Alfa joined the Gastrointestinal Oncology Service at Memorial Sloan-Kettering Cancer Center and Weill Cornell Medical College in New York back in 2001. Dr. Abou-Alfa specializes in the treatment of gastrointestinal malignancies and in particular, hepatocellular carcinoma. Dr. Abou-Alfa received his medical degree from the American University of Beirut, Lebanon, and completed his post-doctoral training at Yale University School of Medicine. His research is dedicated to finding novel therapies and improving the effectiveness current therapies for hepatocellular carcinoma, while continuing to understand the basic mechanisms of the diseases and its therapy. Dr Abou-Alfa has many publications in the field. He led on many occasions, international teams of investigators. Dr. Abou-Alfa serves as the chair of the National Cancer Institute (NCI) Task Force for Hepatobiliary Cancers and the chair of the AIDS Malignancy Consortium (AMC) Non-AIDS Defining Malignancies (NADC) Liver/GI Task Force. Dr Abou-Alfa also chairs the hepatocellular carcinoma subgroup of the Alliance cooperative group, and is a cadre member of both the gastrointestinal cancers and pharmacogenomics and population pharmacology committees. Dr Abou-Alfa who has lectured worldwide on the subject on gastrointestinal malignancies, is also a strong advocate for raising awareness and support for improving the outcome of patients with this disease, and enhancing oncologic education worldwide.
Axel Grothey, MD
Professor of Oncology
Clinical & Translational Science, Mayo Graduate School
Division of Medical Oncology, Department of Oncology
Axel Grothey, M.D., is a consultant in the Division of Medical Oncology, Department of Oncology, at Mayo Clinic. He holds the academic rank of professor of oncology and has teaching/examining privileges in Clinical & Translational Science at Mayo Graduate School. He is a member of Mayo Clinic’s Cancer Center.
Dr. Grothey received his medical degree at Ruhr-Universitat Bochum, Germany, and completed residencies at West-German Tumorcenter and the Institute of Pathology at the University of Essen and a residency and fellowship at the University of Bochum. He also completed a research fellowship at MD Cancer Center at the University of Texas. He joined Mayo Clinic as a consultant in 2005.
Dr. Grothey’s clinical interests focus on gastrointestinal cancers, in particular, colorectal cancer, anti-angiogenesis, signal transduction inhibitors, and clinical trial design and statistics. As a consultant and investigator, his research has been funded by the National Cancer Institute (NCI) and the National Institutes of Health, among other organizations. He currently chairs the NCI colon cancer task force, and serves as vice-chair of the gastrointestinal cancer committee of the Alliance for Clinical Trials in Oncology, an NCI-funded cooperative group. He is also chair of the Academic and Community Cancer Research United (ACCRU) international research network.
He currently holds professional positions in the Association of German Internists, German Cancer Association, Working Group of Experimental Cancer Research in Germany, American Association for Cancer Research, European Association for Cancer Research, American Society for Cell Biology, MD Anderson Associates, American Society of Clinical Oncology, European Society for Medical Oncology, German Association for Internal Oncology and the Minnesota Medical Association. He also has served in various leadership positions at Mayo Clinic Cancer Center.
Dr. Grothey serves in journal review and editorial activities for numerous medical journals and is editor for Clinical Colorectal Cancer, Emerging Cancer Therapeutics, PracticeUpdate Oncology, and Therapeutic Advances in Medical Oncology. In educational activities, he has served as a teacher, and he is a five-time recipient of Teacher of the Year recognition at Mayo Clinic. Dr. Grothey has given numerous international, national and regional presentation, as well as invited and visiting professor presentations. He has co-authored more than 250 articles, books, book chapters, editorials, abstracts and letters.
Dr. Wendy Lam, B Sc. (Pharm), MD, FRCPC
Hematologist and Medical Oncologist
Burnaby Hospital Regional Cancer Center
Director, BC Community Oncology Trialists
Dr. Wendy Lam is a hematologist and medical oncologist at the Burnaby Hospital Regional Cancer Centre.
She received her B.Sc (Pharmacy) at Dalhousie University and her MD from University of British Columbia. She then completed her Internal Medicine residency at UBC and Hematology fellowship at McMaster University.
She is the Founding Director of the British Columbia Community Oncology Trialists (BC Cot), which is a collaborative group of oncologists and hematologists involved in clinical research.
Her other interests include education of patients through meeting with patient groups. She has also been instrumental in organizing meetings for continued medical education.
She is Director of the Society of Hematology and Oncology of BC at British Columbia Medical Association
Howard Lim, MD, PhD, FRCPC
Division of Medical Oncology, BC Cancer Agency, Vancouver Centre
Clinical Associate Professor, University of British Columbia
Chair, GI Tumor Group
Program Director, Medical Oncology Residency Training Program
Dr. Howard Lim is a Medical Oncologist with a specialty in gastrointestinal cancer at the BC Cancer Agency in Vancouver. He is currently the Program Director of the Residency Training Program and Chair of the Provincial Gastrointestinal Group. He is currently involved in the Personalized Oncogenomics Program utilizing whole genome sequencing and RNA expression technology as part of precision medicine for oncology care. He is active in clinical trials with the CCTG and is on the NCI Gastro-esophageal task force.
Jonathan Strosberg, MD
Section Head, Neuroendocrine Tumor Program
Chair, GI Research Committee
Chair, Scientific Review Committee
H. Lee Moffitt Cancer Center
Dr. Jonathan Strosberg is an associate professor at the H. Lee Moffitt Cancer Center, specializing in management of gastrointestinal and neuroendocrine malignancies. He is a graduate of Harvard University and Cornell University Medical College, and completed his residency and fellowship training programs at Georgetown University Hospital and H. Lee Moffitt Cancer Center. He leads the neuroendocrine tumor division at Moffitt and heads the gastrointestinal department research program. He also serves as chair of the scientific review committee.
Dr. Strosberg has published over eighty articles on the diagnosis and management of neuroendocrine malignancies in the Lancet, Journal of Clinical Oncology, Annals of Oncology, Annals of Surgery, Cancer, and other major journals, and has written twelve articles for UptoDate. He is a recipient of the National Cancer Institute’s Clinical Investigator Team Leadership Award. He serves on the board of directors of the North American Neuroendocrine Tumor Society (NANETS), on the neuroendocrine guidelines committee of the National Comprehensive Cancer Network (NCCN), and on the neuroendocrine task force of the National Cancer Institute (NCI) and the neuroendocrine staging committee of the American Joint Committee on Cancer (AJCC).
Aravind Arepally, MD, FSIR
Adjunct Professor of Radiology
Vanderbilt University School of Medicine
Aravind Arepally is an Interventional Radiologist at Piedmont Healthcare, a tertiary referral and transplant center in Atlanta and an Adjunct Professor of Radiology at Vanderbilt University School of Medicine.
After earning his undergraduate degree in mathematics at Mercer University in Macon, Georgia, Arepally received his medical degree and completed his radiology residency (chief resident) at Emory University School of Medicine, followed by a fellowship in cardiovascular and interventional radiology (chief fellow) at Johns Hopkins University.
While at Johns Hopkins, Arepally was Associate Professor of Radiology and served as clinical director for the Center for Bioengineering Innovation and Design, with a research focus on the development of embolics and cellular delivery for the treatment of diabetes and obesity. Dr. Arepally currently coordinates research projects at Duke University, Johns Hopkins and Mt. Sinai Health System to develop new embolic platforms, including advanced delivery catheter systems, embolic beads for targeted delivery, and new clinical applications for embolization.
Dr. Arepally has authored more than 150 papers, books, and abstracts, and has been a principal investigator or co-investigator on more than 15 grants (five from the NIH). He is the recipient of numerous national awards for his research in the field of MRI, device development, and embolization applications. He also lectures nationally and internationally on minimally invasive therapies with specific interest in the treatment of hepatocellular carcinoma, and radioembolization.
David Liu, MD, FRCP(C,) ABR(D), CAQ(IR)
Clinical Associate Professor
University of British Columbia
Dr David M Liu MD is an Interventional Radiologist with the current appointments of Clinical Associate Professor of Radiology at the University of British. He is board certified in both Canada and the US, and holds appointments at the Vancouver General Hospital, University of British Columbia Hospital and the BC Cancer Agency with a cross appointment in the department of Surgery. Dr Liu received his medical degree from University of Toronto, completed his radiology residency at University of British Columbia, and interventional radiology fellowship at Northwestern Memorial Hospital, and has practiced on both sides of the border. In addition to benchside and clinical research in the fields of novel embolic platforms, ablative technologies and cancer related thromboembolic disease. Dr Liu maintains an active clinical practice interventional oncology practise incorporating all aspects of embolization, ablation, venous access, and palliative therapy in all organ systems. He is the co-founder and co-chair of SHOW, and has been credited with 4 book chapters, over 40 publications, and 70 invited lectures, and is an active member and inducted fellow of the Society of Interventional Radiology. He holds specific interest in the treatment of hepatocellular carcinoma, and metastatic colorectal carcinoma and is actively involved in both translational research and clinical trials.
Wael Saad, MD
Director, Vascular and Interventional Radiology
University of Michigan Health System
Frankel Cardiovascular Center
Ann Arbor, MI
Dr. Saad is a Physician of 20 years and is internationally recognized for liver disease including liver transplantation, hepatobiliary disease and portal hypertension. He has over 240 publications, and over 70 book chapters and is an author of 4 books. He completed his residency at the University of Rochester, New York and his Fellowship in Vascular & Interventional Radiology at Mallinckrodt Institute of radiology, Washington University, St. Louis. He practiced Interventional Radiology at the University of Rochester and University of Virginia before coming to the University of Michigan in 2013. At the University of Virginia he was the program director of the Vascular & Interventional Radiology Fellowship. Dr. Saad is active in the Society of Interventional Radiology (SIR) and was awarded the SIR-Fellowship in 2010. He served as the Chairman of the SIR Standards of Practice Committee from 2011 through to 2014.
Michael Soulen, MD
Professor of Radiology
Professor of Radiology in Surgery
Hospital of the University of Pennsylvania
Education – Medical School: University of Pennsylvania School of Medicine; Residency: Francis Scott Key Medical Center; Residency: Johns Hopkins Hospital; Fellowship: Thomas Jefferson University Hospital
Specialty – Board Certifications: Vascular and Interventional Radiology 1995; Diagnostic Radiology, 1989
Personal Statement – Recognized annually in Philadelphia Magazine’s Top Docs issue from 2004 through 2016; Recognized by America’s Top Doctors, 2007, 2008, 2010, 2012-14; Recognized by Best Doctors in America 2003-2004, 2005-2006, 2007-2008, 2009-2010, 2011-2012, 2013-2014
David Valenti, MD, CM, FRCP(C)
Head, Interventional Radiology Division
Director, Interventional Radiology Fellowship Program
Dr David Valenti, MD, is an Interventional Radiologist at McGill University in Montreal Canada. He is the head of the IR Division of the McGill University Health Centre and is the Director of the Interventional Radiology Fellowship Program at McGill. Dr Valenti earned his medical degree at McGill and also did his Radiology training and IR Fellowship at McGill. Prior to his Fellowship he worked for 2 years as a management consultant with McKinsey & Company, a large global strategy management consulting firm. Following fellowship he joined the faculty at McGill. He is credited with one book chapter and over 35 publications and 50 invited lectures. He serves on the boards of the Association of Radiologists of Quebec and the Canadian Interventional Radiology Association, as well as various hospital and practice committees. In addition to his administrative duties he is active clinically in all aspects of embolization, including UFE, oncology, trauma, etc..,. ablation, venous access, venous thrombo-embolic disease, transplant interventions and other areas.
Thomas A. Aloia, MD
Associate Professor, Surgical Oncology
The University of Texas M.D. Anderson Cancer Center
Dr. Thomas Aloia is a Hepatobiliary Surgical Oncologist in the Gastrointestinal Center at the University of Texas MD Anderson Cancer Center.
Dr. Aloia received his medical degree from the University of California – Los Angeles Geffen School of Medicine. His postgraduate training included a general and thoracic surgery residency at Duke University Medical Center and fellowships in Surgical Oncology at MD Anderson and Hepatobiliary/Liver Transplantation at the Paul Brousse Hospital in Paris, France. He has recently completed a Certificate in Healthcare Management at the Rice University (Jones) Business School.
Dr. Aloia’s clinical expertise is in hepatobiliary surgery, gastrointestinal surgical oncology, minimally invasive surgery and liver transplantation surgery. He is an ad hoc reviewer for multiple medical and surgical journals and serves on the editorial board of The Journal of Oncology Practice, Surgery, Annals of Surgery and the Annals of Surgical Oncology. He has published over 150 manuscripts related to his areas of research interests including advanced liver imaging techniques, chemotherapy-induced liver injury, enhanced surgical recovery and the medical economics of cancer surgery.
At MD Anderson, he has focused his administrative efforts in the areas of patient safety, quality, and functional outcomes including his role as the ACS NSQIP Surgeon Champion and as the Chair of the Division of Surgery Continuous Quality Improvement Committee.
Recently, Dr. Aloia was appointed as Program Director of the Department of Surgical Oncology’s Hepatopancreatobiliary Surgery and International Surgical Oncology Fellowship Programs, Associate Medical Director of the MD Anderson Gastrointestinal Disease Center, Deputy Department Chair for Education, and Associate Head of the Institute for Cancer Care Innovation.
Sean P. Cleary BScH, MD, MSc, MPH, FRCSC
Associate Professor, University of Toronto
General Surgery, Pancreatic and Hepatobiliary Surgery
Samuel Lunenfeld Research Institute
Toronto General Hospital
Sean Cleary is Hepatobiliary and Pancretic Surgical Oncologist and an Associate professor in the Department of Surgery at the University of Toronto. He received a BScH from Queen’s University and his MD from the University of Western Ontario. He completed a General Surgery residency and fellowship training in Hepatobiliary and Pancreatic Transplantation and Surgical Oncology at the University of Toronto. In addition he obtained a Masters of Science in Cancer Genetics followed by a MPH in Public Health and Epidemiology in the Dala Lana School of Public Health at the University of Toronto. Sean is a staff surgeon in the Divisions of General Surgery and Surgical Oncology at the Toronto General Hospital and a Research Associate in the Prosserman Centre for Health Research at the Lunenfeld-Tanenbaum Research Institute. His clinical interests include the surgical treatment of pancreatic, hepatic and biliary malignancies with a specific focus on minimally invasive approaches to these cancers. His research interests include the genetic epidemiology of pancreatic and hepatocellular cancers.
Paul Hansen, MD, FACS
Chief of Surgical Oncology
Program Director, Liver and Pancreas Surgery
Portland Providence Cancer Center
Paul D. Hansen, M.D. is the Director of the Hepatobiliary Program and the Medical Director for the Surgical Oncology Program at Providence Portland Medical Center. Dr. Hansen also serves as Program Director for the hepatobiliary and pancreatic surgery postgraduate fellowship program.
Dr. Hansen completed medical school at the University of Washington School of Medicine, and residency in general surgery at the University of California – San Francisco. Dr. Hansen went on to complete fellowships in Hepatobiliary and Pancreatic Surgery at the Royal College of Medicine at Hammersmith Hospital in London, England, and in Laparoscopy and Surgical Endoscopy at Legacy Portland Hospitals/Oregon Health and Science University in Portland, Oregon.
Dr. Hansen has helped to pioneer minimally invasive approaches to liver and pancreatic cancers, and has advanced research in laparoscopic liver tumor ablation (RFA), as well as laparoscopic-assisted liver chemotherapy, including laparoscopic chemotherapy pump placement, and laparoscopic assisted chemo-embolization.
Dr. Hansen currently serves as the State Chair for the Committee on Cancer and is actively involved in many surgical societies such as the American Hepato-Pancreato-Biliary Society, Society of Surgical Oncologists, Society of American Gastrointestinal Endoscopic Surgeons, Society for Surgeons of the Alimentary Tract, Pacific Coast Surgical, the American College of Surgeons, and Portland Surgical Society. Dr. Hansen annually volunteers for overseas medical missions to countries such as Pakistan, Guatemala, Vietnam, and Cambodia.
Calvin H.L. Law, MD, MPH, FRCSC
Chief, Odette Cancer Centre, Sunnybrook Health Sciences Centre
Regional Vice President, Cancer Care Ontario, Toronto Central North
Professor, University of Toronto
Dr. Calvin Law is the Chief, Edmond Odette Cancer Centre, Sunnybrook Health Sciences Centre and Regional Vice President, Cancer Care Ontario. He is also a cancer surgeon specializing in hepatobiliary, pancreatic and gastrointestinal surgical oncology.
As a leader, Dr. Law has held several leadership positions prior to his current role including being the Cancer Care Ontario Head and Regional Lead of Surgical Oncology for Toronto Central North and the Chair for Gastrointestinal Oncology Site Group at the Edmond Odette Cancer Centre. He was also the co-founder of the Susan Leslie Clinic for Neuroendocrine Tumours.
From an academic point of view, Dr. Law holds the rank of Full Professor at the University of Toronto in the Department Surgery and the Department of Health Policy, Management and Evaluation. He also serves as an Affliliate Scientist at Sunnybrook Research Institute and has served as an Adjunct Scientist for the Institute of Clinical Evaluative Sciences. Dr. Law was the inaugural holder of the Sherif and Mary- Lou Hanna Research Chair in Surgical Oncology at the University of Toronto. He has also completed a term as a Career Scientist for the Ministry of Health and Long Term Care of Ontario. His research focuses on health services research and population outcomes, where he has published over 120 peer reviewed publications.
As an educator, Dr. Law has been recognized with teaching awards at the undergraduate, graduate and post-graduate levels, including the Canadian Association of General Surgery Resident Teaching Award, the Bruce Tovee Surgical Teaching Award and the Robert Mustard Mentorship Award. He has also served a term as an Examiner for the Royal College of Physicians and Surgeons of Canada.
Dr. Law completed his medical school training at the University of Toronto, after which time he travelled to McMaster University to complete his General Surgery training. He returned to the University of Toronto to complete his Surgical Oncology Fellowship training and went on to Cambridge, Massachusetts to complete his Masters of Public Health at Harvard University. He then returned to Canada, and settled at the University of Toronto, and Sunnybrook Health Sciences Centre.
Lee Swanstrom, MD, FACS, FASGE, FRCSEng(hon)
Directeur de l’Innovation, IHU-Strasbourg
Clinical Professor of Surgery, Oregon Health & Science University
Division of GI and Minimally Invasive Surgery, Oregon Clinic
Dr. Lee Swanström heads the Division of GI and Minimally Invasive Surgery at the Oregon Clinic and is Director of the Providence Health System’s Complex GI and Foregut Surgery Postgraduate Fellowship Program. In addition, he is Clinical Professor of Surgery at Oregon Health and Science University, is a Director of the American Board of Surgery and is Past President of the Society of American Gastrointestinal Endoscopic Surgeons (SAGES) and of the Fellowship Council (FC). In 2010, he became the Chief Innovations Officer of the Institutes des Hôpitaux Universitaires of the University of Strasbourg, France, where he additionally directs the Innovations Fellowship program (I-SIP). His clinical practice is primarily surgical endoscopy and foregut surgery.
Dr. Swanström received his MD degree from Creighton University following undergraduate work at the University of Paris and University of Colorado. He completed an internship and residency in general surgery in Portland and a fellowship in surgical endoscopy and GI surgery at the University of Western Ontario.
Dr. Swanström’s clinical focus is on minimally invasive treatments of a variety of esophageal and gastrointestinal disorders, particularly utilizing laparoscopy and interventional flexible endoscopy. He is a well known researcher with over 350 published papers, 66 book chapters and is the editor of 2 major surgical textbooks and the journal Surgical Innovation. His research focus is in foregut physiology, human factors and technology assessment and new procedure development. This has resulted in 15 patents and a successful medical device startup company. Most recently he founded and directs Lumen Surgical – a startup in the field of interventional endoscopy. He is and has been an investigator on numerous outcomes research studies for new procedures such as NOTES to determine their safety and efficacy for establishing new standards of care. He has served as a consultant to a large number of past and current medical device companies but his greatest pride has been the large numbers of fellows and residents he has trained and who have been inspired to push the envelope in the field of GI surgery.
Laura Dawson, MD, MPH, FRCSC
Department of Radiation Oncology
University of Toronto
Dr. Laura Dawson is a radiation oncologist at the Princess Margaret Cancer Centre, and a Professor the Department of Radiation Oncology, University of Toronto. She completed her medical school and radiation oncology residency at the University of Toronto and a fellowship in high precision radiation therapy at the University of Michigan, where she stayed on as a faculty member until 2003, at which time she returned to Canada to develop a hepatobiliary radiation therapy program at the Princess Margaret Cancer Centre. She is an internationally recognized leader in hepatobiliary and liver metastases radiation therapy and in the use of advanced radiation technologies, including stereotactic body radiation therapy (SBRT) and image guided radiation therapy (IGRT). She is the principal investigator of several phase III clinical trials, including RTOG1112, an international randomized trial of SBRT for locally advanced hepatocellular carcinoma and HE.1, a Canadian randomized trial of low dose whole liver radiation therapy to treat painful liver cancer, unsuitable for other treatment. She has published over 150 scientific papers. She was a recipient of an ASCO career development award, and her research has been funded by the NIH, CIHR, NCIC CTG, and the Canadian Cancer Society.
Andrew Kennedy, MD
Physician in Chief, Radiation Oncology
Director, Radiation Oncology Research
Sarah Cannon Research Institute
Dr. Kennedy is currently Physician in Chief, Radiation Oncology, and Director, Radiation Oncology Research, Sarah Cannon Research Institute, Nashville, TN, USA. In addition he is adjunct associate professor of Department of Mechanical and Aerospace Engineering and Department of Biomedical Engineering at North Carolina State University, Raleigh, North Carolina, USA. He is a noted expert radiation oncologist in gastrointestinal cancers and was instrumental in reintroducing liver radiotherapy via Yttrium-90 microspheres into the USA in August 2000.
Nationally he serves as a member of the Board of Chancellors for the American College of Radiation Oncology and is a Fellow of the College. Clinically he has been selected yearly since 2009 as one of America’s Best Doctors by peers, and was inducted into Alpha Omega Alpha Honor Society as a faculty member in 1999. Dr. Kennedy is a graduate of Loma Linda School of Medicine, in Loma Linda, CA, USA and completed residency at The University of North Carolina at Chapel Hill, NC, USA. He served as an associate professor in the Radiation Oncology, Head of GI Radiation Oncology at The University of Maryland School of Medicine, and also Radiation Oncology Residency Program Director from 1997-2002.
James M. Metz, MD
Professor and Chair
Executive Director, OncoLink
Hospital of the University of Pennsylvania Perelman Center for Advanced Medicine
James M. Metz, MD, is the Henry K. Pancoast Professor and Chair of Radiation Oncology in the Perelman School of Medicine at the University of Pennsylvania.
Dr. Metz specializes in treatment of gastrointestinal (GI) malignancies and retreatment of previously irradiated tumors. He leads numerous clinical trials in GI cancer with an interest in maintaining normal organ function. His clinical research emphasizes multimodality therapies for locally advanced GI malignancies. In 2010, Dr. Metz led development of the Roberts Proton Therapy Center, the world’s largest proton center. He is an international leader in the integration of proton therapy in the cancer treatment paradigm.
As Editor-in-Chief (now Executive Director) of OncoLink, an award winning website and resource for cancer information, he pioneered the use of online cancer education and information. OncoLink (www.OncoLink.org) has been named on numerous occasions as one of the Top 10 medical websites world-wide by the National Library of Medicine.
William F. Regine MD, FACR, FACRO
Professor, Radiation Oncology
Chair, Department Of Radiation Oncology
University of Maryland
William F. Regine is the Isadore and Fannie Schneider Foxman Chairman and Professor of Radiation Oncology at the University of Maryland, ranked top 5 in the country in the most recently published NIH rankings. A graduate of the of the State University Health and Science School of Medicine in Syracuse N.Y., Dr. Regine obtained his training at Thomas Jefferson University Hospital in Philadelphia where he also completed a Radiation Oncology Fellowship in Gastrointestinal and Head and Neck malignancies (inclusive of training at the University of Florida). Dr. Regine is considered a National and International expert in the area of GI and CNS malignancies, as well as in the use of Stereotactic Radiosurgery. His first faculty appointment was at St. Jude’s Children’s Cancer Research Hospital where as a Clinical Investigator he helped redefined new standards of care in children with rhabdomyosarcomas. After 2 years at St. Jude he dedicated his career to clinical research in adult cancer patients. He has since served as Principal Investigator or Co-Principal Investigator in at least 4 national NCI sponsored cooperative group clinical trials. He served as the Principal Investigator/Study Chairman of the U.S. Intergroup/ Radiation Therapy Oncology Group (RTOG) 9704 study evaluating adjuvant therapy in patients with pancreatic cancer published in the Journal of the American Medical Association (JAMA) earlier this year. This study defined a new standard of care for patients with pancreatic cancer. He has also been the Radiation Oncology Principal Investigator/Study Chairman of at least 2 additional Institutional clinical trials published in JAMA and the Lancet which defined new standards of care for patients with brain metastases and malignant spinal cord compression. He is co-Editor “Principles and Practices of Stereotactic Radiosurgery”, the first comprehensive textbook of its kind. In addition, he is also a member of the GI and Brain Tumor steering committees for the RTOG/NRG and was the Chairman of the GI section of the National Oral Board examination for trainees in Radiation Oncology.
Diana N. Ionescu, MD, FRCP(C), FCAP
Consultant Pathologist Medical Director Clinical Trials
BC Cancer Agency
Clinical Professor, Department of Pathology and Laboratory Medicine
AP Residency Program Director
University of British Columbia
Dr. Ionescu is a graduate of University of Medicine and Pharmacy “Iuliu Hatieganu” in Cluj Napoca, Romania. She completed her postgraduate training in Anatomical and Clinical Pathology at the University of Pittsburgh Medical Center and a Fellowship in Gynecological Pathology at Vancouver General Hospital. She has practiced as a Consultant Pathologist at BC Cancer Agency in Vancouver since 2006. She is currently a Clinical Professor of Pathology at UBC and serves as the residency program director for the Anatomic Pathology Residency Program.
Her specific areas of diagnostic expertise are lung, gynecologic and breast pathology. She is an author of over 35 scientific publications and book chapters. She is the author and invited speaker at numerous regional, national and international lectures. Her investigation interests include oncologic pathology and molecular biomarkers, lung cancer and adult health education. She is the Canadian Anatomic and Molecular Pathology (CAMP) course director.
Dr. Ionescu is an enthusiastic advocate of pathologists participating in numerous patient education forums, TV shows, advocacy campaigns, being an Medical Advisor for Lung Cancer Canada and most recently appearing before the House of Commons Committee on Health.
E. Celia Marginean, MD, FRCPC, FCAP
Pathologist, Ottawa Hospital
Head, Gastrointestinal Pathology Section
Deputy Director Section of Cytopathology
Associate Professor, Department of Pathology, University of Ottawa
Dr. E. Celia Marginean is a graduate of University of Medicine and Pharmacy “Victor Babes” in Timisoara, Romania. She completed her postgraduate training in Anatomical and Clinical Pathology at St. Barnabas Medical Center, Livingston, NJ, followed by a Fellowship in Gastrointestinal Pathology at YaleUniversity, New Haven, CT and a Cytopathology fellowship at MD Anderson Cancer Center, Houston,TX. She has practiced as a Staff Pathologist at The Ottawa Hospital in Ottawa since 2005. Currently she is the Head of the Gastrointestinal Pathology Section and Deputy Director of the Section of Cytopathology. She holds the rank of Associate Professor of Pathology at University of Ottawa. Her specific areas of diagnostic expertise are Gastrointestinal, liver and pancreas Pathology. She is an author of over 35 scientific publications and book chapters. She has been an invited speaker at numerous regional, national and international lectures.
David Owen, MD, FRCPC
Consultant Pathologist Vancouver General Hospital
Clinical Professor, Department of Pathology and Laboratory Medicine, UBC
Dr. Owen received his medical education at the Welsh National School of Medicine in Cardiff, Wales. He graduated in 1967 and after internship he undertook research training in experimental pathology at the University of Oslo in Norway. He returned to England in 1969 for residency and fellowship training in Anatomical Pathology at St. Thomas’ Hospital Medical School in London. In 1976 he immigrated to Canada where he spent four years at the University of Manitoba in Winnipeg before moving to Vancouver in 1980. He is now Consultant Pathologist at Vancouver General Hospital and Professor of Pathology and Laboratory Medicine at the University of British Columbia.
Dr. Owen’s major interest is in pathology of the gastrointestinal tract, liver and pancreas. He has authored or co-authored more than 150 articles in refereed scientific journals, contributed chapters to over ten textbooks and co-authored three textbooks. He has been Visiting Professor at universities in Hong Kong, Peoples Republic of China, South Africa and Zimbabwe. He has been an invited speaker at the US Canadian Academy of Pathology, the International Academy of Pathology, and ASCP annual meetings. He is currently a member of the editorial board of Modern Pathology.